Dr. Mason Marks
Florida Bar Health Law Section
Professor, Florida State University College of Law
BIO
Dr. Mason Marks is the Florida Bar Health Law Section Professor at Florida State University College of Law. He is the senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and an affiliated fellow at the Information Society Project at Yale Law School. Marks was previously a resident fellow at the Edmond J. Safra Center for Ethics at Harvard University, a research scholar at the Information Law Institute at NYU Law School, and a visiting fellow at Yale Law School.
Marks's academic research focuses on health technology, FDA regulation, and constitutional law. He is particularly interested in state and federal controlled substance regulation, health privacy, and the application of artificial intelligence to medical decision making. His academic writing has been published or is forthcoming in the Duke Law Journal, the Harvard Law Review Forum, the Boston University Law Review, UC Irvine Law Review, the UC Davis Law Review, the Administrative Law Review, the Yale Journal of Law and Technology, the NYU Journal of Legislation and Public Policy, and books by Cambridge University Press.
In addition to legal scholarship, Marks writes about law and technology for publications such as The Washington Post, the Los Angeles Times, The Guardian, The Seattle Times, Slate, WIRED, Vice News, Gizmodo, STAT News, and the Houston Chronicle. His legal commentary has been featured by The New York Times, The Wall Street Journal, The Washington Post, ABC News, Fox News, Bloomberg News, the Telegraph, Radio Boston, German Public Radio, and NPR's All Things Considered.
At Florida State University, Marks teaches Constitutional Law, Drug Law, and Legislation and Regulation. In addition to teaching and research, he is an attorney of council at the international law firm Harris Bricken. An expert on the fast-emerging psychedelics industry, he has presented his research at the Food and Drug Administration, the Department of Health and Human Services, and the National Academies of Sciences, Engineering, and Medicine.
Marks has advised city, state, and federal officials on the rapidly evolving regulatory landscape regarding psychedelics. He served as a founding member of the Oregon Psilocybin Advisory Board, where he chaired the Licensing Subcommittee, and drafted psychedelics legislation adopted by the Washington State Legislature and the Seattle City Council.
Insights
- Coming Soon
